DalsnaFinance Account

Boston Scientific $BSX

Health Care · Health Care Equipment · NYSE/NASDAQ

S&P 500 Russell 1000 Massachusetts

Create a scorecard

$41.95

-0.24 (-0.58%)

As of Oct 7, 2026, 2:32 PM EDT

Price history

Loading chart…

Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Jul 28, 2026, the first target we tracked for BSX.

Boston Scientific (BSX) is trading down at $41.95 (-0.58%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.

Analyst price targets on BSX

Current price targets from 4 firms average $62, median $60, ranging from $54 to $74 — the average is 48% above the current $42. Each is tracked to its date and scored the same way a member's call is.

Bernstein $42.4 → $54 by Oct 2027 Outperform Oct 5, 2026 via Investing.com · Bernstein's track record
Stifel $48.2 → $60 by Aug 2027 Buy Aug 26, 2026 via Investing.com · Stifel's track record
BTIG $46 → $60 by Jul 2027 Buy Jul 29, 2026 via Investing.com · BTIG's track record
UBS $46.1 → $74 by Jul 2027 Buy Jul 28, 2026 via Investing.com · UBS's track record

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Boston Scientific revenue & net income history (FY2016–FY2025)

RevenueNet income

Boston Scientific annual financial statements
	FY2016Dec 2016	FY2017Dec 2017	FY2018Dec 2018	FY2019Dec 2019	FY2020Dec 2020	FY2021Dec 2021	FY2022Dec 2022	FY2023Dec 2023	FY2024Dec 2024	FY2025Dec 2025
Income statement
Revenue	$9.08B	$9.05B	$9.82B	$10.7B	$9.91B	$11.9B	$12.7B	$14.2B	$16.7B	$20.1B
Growth (year over year)	+12.5%	−0.3%	+8.6%	+9.3%	−7.7%	+19.9%	+6.7%	+12.3%	+17.6%	+19.9%
Gross profit	$5.96B	$6.46B	$7.01B	$7.62B	$6.45B	$8.18B	$8.73B	$9.90B	$11.5B	$13.9B
Gross margin	65.7%	71.3%	71.4%	71.0%	65.0%	68.8%	68.8%	69.5%	68.6%	69.0%
Operating income	$447.0M	$1.28B	$1.51B	$1.52B	−$80.0M	$1.20B	$1.65B	$2.34B	$2.60B	$3.61B
Operating margin	4.9%	14.2%	15.3%	14.1%	−0.8%	10.1%	13.0%	16.5%	15.5%	18.0%
Net income	$347.0M	$104.0M	$1.67B	$4.70B	−$115.0M	$985.0M	$642.0M	$1.57B	$1.85B	$2.90B
Net margin	3.8%	1.1%	17.0%	43.8%	−1.2%	8.3%	5.1%	11.0%	11.1%	14.4%
EPS (diluted)	$0.25	$0.08	$1.19	$3.33	−$0.08	$0.69	$0.45	$1.07	$1.25	$1.94
Balance sheet
Cash and equivalents	$196.0M	$188.0M	$146.0M	$217.0M	$1.73B	$1.93B	$928.0M	$865.0M	$414.0M	$1.97B
Total assets	$18.1B	$19.0B	$21.0B	$30.6B	$30.8B	$32.2B	$32.5B	$35.1B	$39.4B	$43.7B
Total liabilities	$11.4B	$12.0B	$12.3B	$16.7B	$15.5B	$15.6B	$14.9B	$15.6B	$17.4B	$19.2B
Long-term debt	$5.42B	$3.81B	$4.80B	$8.59B	$9.13B	$8.80B	$8.91B	$8.57B	$8.97B	$11.1B
Shareholders' equity	$6.73B	$7.01B	$8.73B	$13.9B	$15.3B	$16.6B	$17.6B	$19.3B	$21.8B	$24.2B
Cash flow
Operating cash flow	$1.18B	$1.43B	$310.0M	$1.84B	$1.51B	$1.87B	$1.53B	$2.50B	$3.44B	$4.53B
Capital expenditure	$376.0M	$319.0M	$316.0M	$461.0M	$376.0M	$554.0M	$588.0M	$711.0M	$790.0M	$876.0M
Free cash flow	$806.0M	$1.11B	−$6.00M	$1.38B	$1.13B	$1.32B	$938.0M	$1.79B	$2.65B	$3.66B
Dividends paid	—	—	$0	$0	$28.0M	$55.0M	$55.0M	$28.0M	$0	—
Share buybacks	$0	—	$0	$0	$535.0M	$0	$0	—	—	—

RevenueNet income

Boston Scientific quarterly financial statements
	Q3 FY24Sep 2024	Q4 FY24^†Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25^†Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Income statement
Revenue	$4.21B	$4.56B	$4.66B	$5.06B	$5.07B	$5.29B	$5.20B	$5.44B
Growth (year over year)	+19.3%	+22.5%	+20.9%	+22.8%	+20.3%	+15.8%	+11.6%	+7.5%
Gross profit	$2.90B	$3.10B	$3.21B	$3.42B	$3.54B	$3.68B	$3.61B	$3.85B
Gross margin	68.8%	67.8%	68.8%	67.7%	69.9%	69.6%	69.5%	70.7%
Operating income	$733.0M	$675.0M	$921.0M	$819.0M	$1.05B	$825.0M	$1.10B	$1.18B
Operating margin	17.4%	14.8%	19.8%	16.2%	20.7%	15.6%	21.2%	21.6%
Net income	$469.0M	$565.0M	$674.0M	$797.0M	$755.0M	$672.0M	$1.34B	$907.0M
Net margin	11.1%	12.4%	14.5%	15.7%	14.9%	12.7%	25.8%	16.7%
EPS (diluted)	$0.32	$0.38	$0.45	$0.53	$0.51	$0.45	$0.90	$0.61
Balance sheet
Cash and equivalents	$2.50B	$414.0M	$725.0M	$534.0M	$1.27B	$1.97B	$1.45B	$539.0M
Total assets	$38.1B	$39.4B	$40.1B	$41.6B	$42.7B	$43.7B	$44.4B	$45.2B
Total liabilities	$17.1B	$17.4B	$17.7B	$18.9B	$19.1B	$19.2B	$18.2B	$20.0B
Long-term debt	$9.23B	$8.97B	$10.5B	$11.1B	$11.1B	$11.1B	$11.0B	$10.9B
Shareholders' equity	$20.7B	$21.8B	$22.2B	$22.4B	$23.4B	$24.2B	$25.9B	$24.9B
Cash flow
Operating cash flow	$1.00B	$1.46B	$541.0M	$1.29B	$1.34B	$1.36B	$348.0M	$1.47B
Capital expenditure	$179.0M	$277.0M	$187.0M	$157.0M	$181.0M	$351.0M	$177.0M	$195.0M
Free cash flow	$823.0M	$1.18B	$354.0M	$1.13B	$1.16B	$1.01B	$171.0M	$1.28B
Dividends paid	$0	$0	—	—	—	—	—	—

From Boston Scientific's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Boston Scientific

Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Source: Wikipedia — Boston Scientific